Information Provided By:
Fly News Breaks for January 18, 2017
MYGN
Jan 18, 2017 | 07:13 EDT
Deutsche Bank analyst Dan Leonard started Myriad Genetics with a Sell rating and $15 price target, as he thinks the downside from added share loss in hereditary cancer testing outweighs potential upside newsflow around biomarkers for the PARP inhibitor class.
News For MYGN From the Last 2 Days
There are no results for your query MYGN